Clinical trial · Observational
A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening
Pilot Study of a Dedicated MR of the Pancreas: Improving Screening for Patients at High Risk for Pancreas Cancer
NCT07612046CI-TRIAL-00117383recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to develop a dedicated MRI scan of the pancreas (MRP) to better detect pancreatic cancer in people who are at a high risk for pancreatic cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreas Cancer | Pancreatic Carcinoma | ALIAS | 0.90 |
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Endoscopic ultrasound | Diagnostic Test | — | UNRESOLVED |
| MRI | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Participants at high risk for pancreas ductal adenocarcinoma
- description
- Participants will be high-risk individuals enrolled in the Memorial Sloan Kettering Pancreatic Tumor Registry
- interventionNames
- Diagnostic Test: MRI
- Diagnostic Test: Endoscopic ultrasound
Primary outcomes (1)
- measure
- Compare image quality of novel high-resolution magnetic resonance pancreas (MRP) to conventional MRCP
- timeFrame
- Up to 3 years
- description
- Develop and pilot a focused high-resolution magnetic resonance pancreas (MRP) exam to help facilitate early pancreatic cancer detection in high-risk individuals. Image quality for T1, T2, and DWI sequences performed on the novel MRP exam will be compared to conventional MRCP performed in the same participants.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Two first-degree relatives with pancreas cancer, one being a first-degree relative to the individual * Pathogenic mutation in APC, BRCA1, MLH1, MSH2, MSH6, PMS2, EPCAM, PALB2, or TP53 and a first/second-degree relative with pancreas cancer * Pathogenic mutation in CDKN2A/p16, STK11, PRSS1, SPINK1/PST1, CTRC, CPA1, ATM, or BRCA2 * Meets surveillance age eligibility, which is typically age 50, or 10 years earlier than the youngest relative with pancreas cancer. For individuals with certain gene mutations, this can be earlier. All participants must be aged 21+ For this pilot MRP study, we will additionally apply the following Criteria: * Consents to follow-up contact * US residents * Completed MRI with MRCP with no actionable findings related to the pancreas (e.g. a pancreatic mass) * No metallic artifacts covering the pancreas on prior MRCP * Scheduled for endoscopic ultrasound * No new contraindications for MRI (e.g. new MR unsafe device) * No history of claustrophobia or use of anxiolytic on prior MRI * No history of abdominal surgery that may affect interpretation of either EUS or MR * No medical conditions that confers increased and/or unacceptable risk for anesthesia We will recruit surveillance participants who had at least one prior MRCP in the last 3 years. They must also undergo a same-day EUS procedure as part of their surveillance. Nearly all active cohort participants have had at least one recent MRCP and, on average, our Registry gastroenterologist Dr. Rolston performs EUS in \~260 surveillance participants per year. Accordingly, it is highly feasible to recruit more than 79 participants in the grant period, and recruitment is constrained by budget. * Documentation of Disease o No pathologic confirmation of disease is necessary * Definition of Disease N/A * Required Organ Function N/A Exclusion Criteria: \-
References
Publications (0)
Data not yet available
No reference posted for this study.